← Human Trials & Peer-Reviewed Studies
ARNEO: A Randomized Phase II Trial of Neoadjuvant Degarelix with or Without Apalutamide Prior to Radical Prostatectomy for High-risk Prostate Cancer
Plain-language guide to PMID 36167599 (2023): placebo-controlled randomized controlled trial study of Degarelix.
Key Facts
- PMID
- 36167599
- Journal
- European urology
- Year
- 2023
- Study type
- Randomized Controlled Trial
- Authors
- Devos G et al. (18 authors)
- DOI
- 10.1016/j.eururo.2022.09.009
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at Degarelix.
High-risk prostate cancer (PCa) patients have a high risk of biochemical recurrence and metastatic progression following radical prostatectomy (RP).
Who Took Part
PubMed tags the participants as men only.
Eligible patients had high-risk PCa and were amenable to RP.
Prior to and following neoadjuvant treatment, pelvic 18F-PSMA-1007 positron emission tomography (PET)/magnetic resonance imaging (MRI) was performed.
How the Study Was Run
The researchers set it up as a randomized and placebo-controlled study.
The participants were allocated by chance, so the Degarelix group and the comparison group should start out alike.
The comparison arm used a placebo, so changes seen with Degarelix could be set against what happens without it.
ARNEO was a randomized, placebo-controlled, phase II neoadjuvant trial before RP performed between March 2019 and April 2021.
In this study, the researchers looked at the difference in pathological responses in high-risk prostate cancer patients treated with degarelix plus apalutamide or degarelix plus matching placebo prior to radical prostatectomy.
What Was Measured
Topics PubMed links to this paper include Prostate, Prostatic Neoplasms, Neoadjuvant Therapy, Prostatectomy, Gallium Radioisotopes, Oligopeptides and Thiohydantoins.
Author keywords: Apalutamide, High-risk prostate cancer, Minimal residual disease, PTEN loss, Prostate-specific membrane antigen positron emission tomography/computed tomography and Residual cancer burden.
What This Means in Plain Language
The paper is a randomized and placebo-controlled study of Degarelix.
Results are reported in around 10 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2023 (European urology), a journal based in Switzerland.
More context: the Degarelix compound page, all human trials.
Our Notes on the Compound
Degarelix: A GnRH antagonist injection (Firmagon) for advanced prostate cancer that lowers testosterone within days without the initial surge seen with agonists.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.